Q2 results today: 18 firms, 3 big banks on Oct 17

Earnings day focus: banks lead the Oct 17 slate

A busy quarterly-results session is lined up for October 17, with 18 companies scheduled to publish their July to September (Q2FY27) numbers. The list includes three of India’s most closely tracked private lenders: HDFC Bank, ICICI Bank, and Axis Bank. Alongside them are public-sector banks such as IDBI Bank, Central Bank of India, and Punjab & Sind Bank. The earnings set also extends beyond financials to sectors such as cement, healthcare, chemicals, industrials, and travel. India Cements and Ixigo are among the non-bank names expected to release results. For investors, a clustered reporting day like this can shift attention quickly across sectors. It also tends to concentrate trading volumes around earnings-related updates and management commentary.

Companies expected to report Q2FY27 results on Oct 17

The companies mentioned as scheduled to announce their July to September earnings include both large-cap and smaller listed names. The list below reflects the firms explicitly referenced.

Why Q2FY27 results matter for financial stocks

With HDFC Bank, ICICI Bank and Axis Bank on the same reporting day, bank earnings are likely to remain a central focus. Results releases typically draw attention to balance-sheet growth, margins, and the direction of credit costs, as well as any changes in deposit trends. Investors also watch for commentary on loan demand and competitive intensity in pricing. The public-sector banks on the list add another layer, as their quarterly updates often influence sentiment on PSU financials. A single-day cluster also makes peer comparisons easier because numbers and commentary hit the market within hours of each other. That said, stock reactions are usually driven by how results compare with market expectations, which can differ by bank. For broader market participants, a heavyweight reporting day can influence intraday indices even if the news is stock-specific.

Beyond banks: cement, travel and smaller corporates

The reporting slate is not limited to lenders. India Cements is among the key non-financial names mentioned for the day, bringing the cement sector into focus alongside bank results. Ixigo’s inclusion adds attention from the travel and consumer-internet segment. The list also includes smaller companies across specialties such as biotech and healthcare, industrial and materials names, and hospitality-related businesses. Rossari Biotech and Bajaj Healthcare are among the names scheduled to report, based on the companies referenced. Kross, Cupid Breweries and Distilleries, Midland Polymers, Indo Cotspin, TGB Banquets and Hotels, Gagan Gases, and Hemo Organic are also cited as part of the day’s results flow. For investors following small and microcaps, quarterly filings can materially change near-term perception on growth and liquidity. In such counters, disclosures around cash flows, working capital and compliance items can sometimes attract as much attention as profit figures.

HOMRE Ltd: sharp sales rise, margin expansion noted

Among the filings referenced, HOMRE Ltd’s Q2 FY27 consolidated update (filed on October 16, 2026) flags a year-on-year operating margin expansion of 451 basis points. The same note also states that H1 FY27 operating cash flow was negative despite a profit. The quarterly table provided shows sales of ₹20.9 crore for September 2026, compared with ₹11.9 crore for June 2026 and ₹2.5 crore for September 2025. Operating profit is shown at ₹0.8 crore for September 2026 versus ₹0.4 crore in June 2026, after a loss around September 2025 (rounded in the table as -0.0). Operating profit margin is listed at 3.7% in September 2026 versus 3.2% in June 2026 and -0.8% in September 2025. Other income is shown at ₹0.1 crore in September 2026, down from ₹0.5 crore in June 2026 and ₹0.2 crore in September 2025. Net profit is listed at ₹0.7 crore for September 2026 versus ₹0.6 crore in June 2026 and ₹0.2 crore in September 2025.

Hemo Organic: compliance update and share sale disclosure

The provided material also includes a compliance disclosure for Hemo Organic Ltd. It states that the company intimated the BSE that Mrs. Pratibha Sharma withdrew her consent to act as Company Secretary and Compliance Officer before the appointment took effect. Separately, the disclosure notes that promoters Dineshbhai and Sonalben Patel agreed to sell 567,958 equity shares, representing 16.38% of Hemo Organic’s paid-up capital. The same excerpt states that four buyers, including individuals, an LLP, and a trust, will acquire the shares. In addition, a separate news line referenced indicates Hemo Organic Limited announced the resignation of Yukta Prakash Patel as company secretary and compliance officer, effective September 19, 2026. These items matter because governance and compliance continuity are closely watched in small-cap companies. Ownership changes of this scale can also become a key data point for shareholders tracking promoter holding trends.

Hemo Organic’s reported quarterly snapshots: what the excerpts show

The supplied snippets include multiple blocks showing upcoming and last earnings dates, and summary metrics that repeat in places. One section states the upcoming earnings date for Hemo Organic Ltd is October 17, 2026, with the last earnings date shown as July 15, 2026 (Q1 FY26-27). The excerpted summaries show revenue as ₹0.00 crore for June 2026 (Q1 FY27). Net profit figures in the excerpts are not fully consistent: one “About” line shows net profit of ₹0.07 crore as on June 2026 (Q1 FY27), while another standalone comparison shows net profit of -₹0.07 crore for Q1 FY27. The same compilation also shows a “Hemo Organic Limited” line with revenue at ₹0.00 crore for Q1 FY27 and expenditure at ₹0.07 crore. The text also states “No Quarterly Earnings Forecast data for the stock” in the provided block. Readers typically rely on the company’s exchange filings for the definitive numbers and context.

Market impact: what to watch as results hit the tape

A reporting-heavy day can lead to rapid rotation in attention across banks and non-financial stocks. For the large banks, the market often reacts quickly to any changes highlighted in the results release and management commentary, with spillovers into sector peers. For smaller companies, trading reactions can be sharper because liquidity is thinner and quarter-on-quarter changes appear large in percentage terms even when absolute values are small. HOMRE’s sales and margin progression, along with the note about negative operating cash flow in H1 FY27 despite profit, is an example of how cash-flow commentary can matter alongside profit numbers. In Hemo Organic’s case, compliance officer changes and a promoter share sale disclosure are the type of events that can influence risk assessment, independent of quarterly revenue and profit. With multiple banks and non-banks reporting on the same day, headline screens can drive short-term volatility. Investors tracking the full slate generally look for clean, comparable disclosures across companies, especially on cash flows, corporate actions, and compliance.

Analysis: why this Oct 17 results cluster stands out

The Oct 17 slate stands out mainly because it combines heavyweight private banks with multiple PSU banks, plus a long tail of smaller companies. That mix can shape broader sentiment, since bank results often act as a proxy for credit conditions while non-bank updates provide sector-specific signals. It is also notable that some smaller-company excerpts place emphasis on disclosures beyond the profit and loss statement, including cash-flow direction and compliance changes. HOMRE’s margin expansion data and the mention of negative operating cash flow despite profit highlights the need to read beyond headline net profit. For Hemo Organic, governance continuity and promoter transactions are central elements of the disclosed updates. The common thread across these filings is that markets tend to reward clarity and consistency in disclosures, particularly during result seasons when comparisons are frequent. As always, the most actionable information comes from the primary exchange filings and the full financial statements.

Conclusion

October 17 brings a crowded Q2FY27 results calendar, led by HDFC Bank, ICICI Bank and Axis Bank, with several PSU banks and smaller corporates also scheduled to report. Alongside financial results, disclosures around cash flows, compliance roles, and promoter transactions are part of the day’s information flow. HOMRE’s reported sales jump and margin expansion, and Hemo Organic’s compliance and promoter-sale disclosures, show why quarterly updates often extend beyond earnings alone. The next key step for investors is to track the formal exchange filings and any management commentary released with the numbers as they are published through the day.